Kenneth Ian Mills

List of Publications by Year
in descending order

167	4,988	117625	106344
papers	citations	34 h-index	65 g-index

174	174	174	7940
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Medicine, 2012, 18, 605-611.	30.7	584
2	Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. Journal of Clinical Oncology, 2010, 28, 2529-2537.	1.6	567
3	Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood, 2005, 106, 3768-3776.	1.4	205
4	An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. British Journal of Haematology, 2008, 142, 802-807.	2.5	173
5	CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia, 2007, 21, 566-568.	7.2	168
6	Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood, 2009, 114, 1063-1072.	1.4	152
7	The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood, 2006, 108, 3494-3503.	1.4	110
8	Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis, 1992, 13, 1035-1038.	2.8	104
9	Dielectrophoretic separation and enrichment of CD34+cell subpopulation from bone marrow and peripheral blood stem cells. Medical and Biological Engineering and Computing, 1995, 33, 235-237.	2.8	103
10	Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis. PLoS ONE, 2013, 8, e69604.	2.5	94
11	Unravelling an HLA-DR Association in Childhood Acute Lymphoblastic Leukemia. Blood, 1999, 94, 694-700.	1.4	92
12	Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica, 2008, 93, 662-669.	3.5	82
13	Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 212-217.	1.9	79
14	Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia, 2007, 21, 2495-2505.	7.2	78
15	Regulation of ABCB1 (p-glycoprotein) by the FOXO1 Transcription Factor in Acute Myeloid Leukemia.. Blood, 2009, 114, 589-589.	1.4	71
16	Increased heterozygosity for MHC class II lineages in newborn males. Genes and Immunity, 2002, 3, 263-269.	4.1	68
17	False-positive results with PCR to detect leukaemia-specific transcript. Lancet, The, 1990, 335, 1037-1038.	13.7	65
18	Gene expression profiling in MDS and AML: potential and future avenues. Leukemia, 2011, 25, 909-920.	7.2	64

#	Article	IF	Citations
19	Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica, 2020, 105, 448-456.	3.5	64
20	RARÎ±-PLZF overcomes PLZF-mediated repression of CRABPI , contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18694-18699.	7.1	62
21	Comprehensive genomic screens identify a role for PLZF-RARÎ± as a positive regulator of cell proliferation via direct regulation of c-MYC. Blood, 2009, 114, 5499-5511.	1.4	53
22	The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. Journal of Translational Medicine, 2018, 16, 360.	4.4	50
23	Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. British Journal of Haematology, 2000, 111, 853-862.	2.5	49
24	c-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leukemia Research, 1998, 22, 899-903.	0.8	48
25	Inhibition of Mitochondrial Function in HL60 Cells Is Associated with an Increased Apoptosis and Expression of CD14. Biochemical and Biophysical Research Communications, 1999, 263, 294-300.	2.1	48
26	Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks. Leukemia, 2006, 20, 1385-1392.	7.2	47
27	Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. British Journal of Haematology, 2008, 141, 483-493.	2.5	46
28	Identification of Gene Expressionâ€“Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2013, 31, 3557-3564.	1.6	45
29	Oncogenic roles of <scp>PRL</scp>â€3 in <scp>FLT</scp>3â€<scp>ITD</scp> induced acute myeloid leukaemia. EMBO Molecular Medicine, 2013, 5, 1351-1366.	6.9	44
30	Human Major Histocompatibility Complex Contains Several Leukemia Susceptibility Genes. Leukemia and Lymphoma, 1994, 12, 211-222.	1.3	43
31	Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood, 2015, 125, 2985-2994.	1.4	42
32	Prognostic and therapeutic relevance of câ€<scp>FLIP</scp> in acute myeloid leukaemia. British Journal of Haematology, 2013, 160, 188-198.	2.5	39
33	HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy. Haematologica, 2013, 98, 1216-1225.	3.5	39
34	DNA methylation: biology and significance. Blood Reviews, 1996, 10, 249-261.	5.7	38
35	Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Annals of Hematology, 2012, 91, 1221-1233.	1.8	37
36	Influence of the major histocompatibility complex on age at onset of chronic lymphoid leukaemia. International Journal of Cancer, 1996, 65, 134-139.	5.1	36

#	Article	IF	Citations
37	THIRD PARTY MEDIATED GRAFT REJECTION DESPITE IRRADIATION OF BLOOD PRODUCTS. British Journal of Haematology, 1992, 80, 251-252.	2.5	34
38	Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study. Breast Cancer Research, 2018, 20, 4.	5.0	33
39	p53 Mutations, Methylation and Genomic Instability in the Progression of Chronic Myeloid Leukaemia. Leukemia and Lymphoma, 1997, 26, 211-226.	1.3	32
40	Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochemical and Biophysical Research Communications, 2005, 333, 703-713.	2.1	32
41	Elevated <scp>TRIB</scp>2 with <scp>NOTCH</scp>1 activation in paediatric/adult <scp>T</scp>â€<scp>ALL</scp>. British Journal of Haematology, 2012, 158, 626-634.	2.5	31
42	Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene-Dependent Model of Cytogenetically Normal Acute Myeloid Leukemia. Stem Cells, 2013, 31, 1434-1445.	3.2	30
43	Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget, 2017, 8, 51429-51446.	1.8	30
44	Epigenetics in Myeloproliferative Neoplasms. Journal of Cellular and Molecular Medicine, 2017, 21, 1660-1667.	3.6	29
45	Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. Blood, 2009, 113, 1203-1204.	1.4	27
46	Repurposing medicinal compounds for blood cancer treatment. Annals of Hematology, 2015, 94, 1267-1276.	1.8	27
47	Differential TERT promoter methylation and response to 5â€²azaâ€²2â€²â€²deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death. Genes Chromosomes and Cancer, 2012, 51, 768-780.	2.8	26
48	Hoxa6 potentiates short-term hemopoietic cell proliferation and extended self-renewal. Experimental Hematology, 2009, 37, 322-333.e3.	0.4	25
49	QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics. BMC Bioinformatics, 2016, 17, 198.	2.6	25
50	Living long and ageing well: is epigenomics the missing link between nature and nurture?. Biogerontology, 2016, 17, 33-54.	3.9	25
51	Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics, 2014, 15, 487.	2.8	24
52	Erythropoietin drives breast cancer progression by activation of its receptor EPOR. Oncotarget, 2017, 8, 38251-38263.	1.8	24
53	Up-regulatedMSI2is associated with more aggressive chronic myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 2105-2113.	1.3	23
54	Characterisation of Genome-Wide PLZF/RARA Target Genes. PLoS ONE, 2011, 6, e24176.	2.5	22

#	Article	IF	Citations
55	Deregulation of Genes Related to Iron and Mitochondrial Metabolism in Refractory Anemia with Ring Sideroblasts. PLoS ONE, 2015, 10, e0126555.	2.5	21
56	Unravelling an HLA-DR Association in Childhood Acute Lymphoblastic Leukemia. Blood, 1999, 94, 694-700.	1.4	21
57	Nuclear factorâ€ºB as a potential therapeutic target for the novel cytotoxic agent LCâ€1 in acute myeloid leukaemia. British Journal of Haematology, 2008, 143, 661-671.	2.5	20
58	A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. Haematologica, 2012, 97, 1380-1388.	3.5	20
59	A childhood acute lymphoblastic leukemia genome-wide association study identifies novel sex-specific risk variants. Medicine (United States), 2016, 95, e5300.	1.0	20
60	The impact of next generation sequencing technologies on haematological research â€“ A review. Pathogenesis, 2015, 2, 9-16.	0.8	19
61	Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients. Leukemia Research, 1996, 20, 771-775.	0.8	18
62	Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells. FEBS Letters, 1998, 440, 158-162.	2.8	18
63	SSX2IP expression in acute myeloid leukaemia: an association with mitotic spindle failure in t(8;21), and cell cycle in t(15;17) patients. British Journal of Haematology, 2007, 140, 071119224223003-???.	2.5	18
64	Significance of NPM1 Gene Mutations in AML. International Journal of Molecular Sciences, 2021, 22, 10040.	4.1	18
65	Homozygous MHC Genotypes and Longevity. Human Heredity, 1994, 44, 271-278.	0.8	16
66	Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget, 2016, 7, 6609-6619.	1.8	16
67	Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors. Cancer Research, 2022, 82, 819-830.	0.9	16
68	The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia. British Journal of Haematology, 2006, 134, 238-239.	2.5	15
69	Immunotherapy of myeloid leukaemia. Cancer Immunology, Immunotherapy, 2007, 56, 943-957.	4.2	15
70	Chronic loss of STAG2 leads to altered chromatin structure contributing to de-regulated transcription in AML. Journal of Translational Medicine, 2020, 18, 339.	4.4	15
71	DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML). Blood Cells, Molecules, and Diseases, 2015, 54, 123-131.	1.4	14
72	Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis. Leukemia Research, 1995, 19, 519-525.	0.8	13

#	Article	IF	Citations
73	FOCAL XANTHOGRANULOMATOUS PYELONEPHRITIS PRESENTING AS A RENAL TUMOR WITH VENA CAVAL THROMBUS. Journal of Urology, 1998, 160, 117-118.	0.4	13
74	Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS ONE, 2015, 10, e0140483.	2.5	13
75	A combined connectivity mapping and pharmacoepidemiology approach to identify existing medications with breast cancer causing or preventing properties. Pharmacoepidemiology and Drug Safety, 2018, 27, 78-86.	1.9	13
76	A molecular signature of dormancy in CD34+CD38- acute myeloid leukaemia cells. Oncotarget, 2017, 8, 111405-111418.	1.8	13
77	Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia. Oncotarget, 2018, 9, 3853-3866.	1.8	13
78	Pim2 cooperates with PML-RARÎ± to induce acute myeloid leukemia in a bone marrow transplantation model. Blood, 2010, 115, 4507-4516.	1.4	12
79	High and low, but not intermediate, <scp>PRAME</scp> expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation. British Journal of Haematology, 2013, 162, 282-285.	2.5	12
80	Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability. Scientific Reports, 2019, 9, 2678.	3.3	12
81	Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3. British Journal of Haematology, 2005, 130, 203-208.	2.5	11
82	Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature. Blood Advances, 2021, 5, 1059-1068.	5.2	11
83	Low-dose salinomycin induces anti-leukemic responses in AML and MLL. Oncotarget, 2016, 7, 73448-73461.	1.8	11
84	High FUS/TLS expression in acute myeloid leukaemia samples. British Journal of Haematology, 2000, 108, 316-321.	2.5	10
85	WTX is rarely mutated in acute myeloid leukemia. Haematologica, 2008, 93, 947-948.	3.5	10
86	Mutational spectrum defines primary and secondary myelofibrosis. Haematologica, 2014, 99, 2-3.	3.5	10
87	GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways. Journal of Hematology and Oncology, 2016, 9, 5.	17.0	10
88	Relevance of TP53 for CLL diagnostics. Journal of Clinical Pathology, 2019, 72, 343-346.	2.0	10
89	Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica, 2013, 98, 576-583.	3.5	9
90	Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer. Biomarkers in Cancer, 2015, 7, BIC.S28378.	3.6	9

#	Article	IF	Citations
91	Inter-Laboratory Evaluation of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia. Molecular Diagnosis and Therapy, 2016, 20, 457-461.	3.8	9
92	Addiction toRunx1is partially attenuated by loss of p53 in the EÎ¼-Myc lymphoma model. Oncotarget, 2016, 7, 22973-22987.	1.8	9
93	Identification of transcription factors expressed during ATRA -induced neutrophil differentiation of HL60 cells. British Journal of Haematology, 1998, 103, 87-92.	2.5	8
94	A Simple PCR/RFLP Analysis Can Differentiate Between Candida albicans, Aspergillus niger, and Aspergillus fumigatus. Molecular Biotechnology, 2003, 24, 229-232.	2.4	8
95	Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia. Frontiers in Bioscience - Landmark, 2008, Volume, 4605.	3.0	8
96	New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients. British Journal of Haematology, 2012, 157, 347-356.	2.5	8
97	Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1. Leukemia Research, 2014, 38, 131-137.	0.8	8
98	Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat. Experimental Hematology, 2019, 79, 26-34.	0.4	8
99	Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study. BMC Cancer, 2020, 20, 804.	2.6	8
100	The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells. Oncotarget, 2019, 10, 3462-3471.	1.8	8
101	Differential Expression of SHP-1 Levels in Chronic Phase and Advanced Disease CML and in AML Patients. Blood, 2012, 120, 1449-1449.	1.4	8
102	Protein migration from transplanted nuclei in Amoeba proteus. II. An electrophoretic study. Experimental Cell Research, 1981, 136, 469-473.	2.6	7
103	AnIn VivoandIn VitroComparison of the Effects of b2-a2 and b3-a2 p210BCR-ABLSplice Variants on Murine 32D Cells. Leukemia and Lymphoma, 2000, 37, 393-404.	1.3	7
104	Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells. Cancer Gene Therapy, 2001, 8, 936-947.	4.6	7
105	Detection and Analysis of DNA Methylation by Pyrosequencing. Methods in Molecular Biology, 2012, 863, 281-292.	0.9	7
106	GATA2 regulates the erythropoietin receptor in t(12;21) ALL. Oncotarget, 2017, 8, 66061-66074.	1.8	7
107	Leukemia Associated Antigens: Their Dual Role as Biomarkers and Immunotherapeutic Targets for Acute Myeloid Leukemia. Biomarker Insights, 2007, 2, 117727190700200.	2.5	6
108	Microarray for Epigenetic Changes: Gene Expression Arrays. Methods in Molecular Biology, 2012, 863, 319-328.	0.9	6

#	Article	IF	Citations
109	Identification of Genes Whose Expression Overlaps Age Boundaries and Correlates with Risk Groups in Paediatric and Adult Acute Myeloid Leukaemia. Cancers, 2020, 12, 2769.	3.7	6
110	The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories. Blood, 2012, 120, 1399-1399.	1.4	6
111	The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. Blood, 2013, 122, 743-743.	1.4	6
112	Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes. Oncotarget, 2017, 8, 115002-115017.	1.8	6
113	Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia. Biomarker Insights, 2007, 2, 69-79.	2.5	6
114	Overview. , 2002, 200, 001-007.		5
115	FUS expression alters the differentiation response to all-trans retinoic acid in NB4 and NB4R2 cells. British Journal of Haematology, 2007, 139, 94-97.	2.5	5
116	Comparison of the survival implications of tumour-associated versus cancer-testis antigen expression in acute myeloid leukaemia. British Journal of Haematology, 2007, 136, 510-512.	2.5	5
117	An integrated meta-analysis approach to identifying medications with potential to alter breast cancer risk through connectivity mapping. BMC Bioinformatics, 2017, 18, 581.	2.6	5
118	Pathways, Processes, and Candidate Drugs Associated with a Hoxa Cluster-Dependency Model of Leukemia. Cancers, 2019, 11, 2036.	3.7	5
119	A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia. Scientific Reports, 2020, 10, 18514.	3.3	5
120	NF Kappa B as a Therapeutic Target in AML.. Blood, 2006, 108, 2587-2587.	1.4	5
121	Comparison of SARS-CoV-2 Evolution in Paediatric Primary Airway Epithelial Cell Cultures Compared with Vero-Derived Cell Lines. Viruses, 2022, 14, 325.	3.3	5
122	Correlation of M-bcr breakpoint with different chromosomal abnormalities in blast crisis Ph1-positive CML. Leukemia Research, 1991, 15, 999-1003.	0.8	4
123	The Relationship Between the Location of the Breakpoint Within the M-BCR and Clinical Parameters. Leukemia and Lymphoma, 1993, 11, 73-79.	1.3	4
124	Identification of Gene Networks Associated with Acute Myeloid Leukemia by Comparative Molecular Methylation and Expression Profiling. Biomarkers in Cancer, 2010, 2, BIC.S3185.	3.6	4
125	Serum profiling identifies ibrutinib as a treatment option for young adults with Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 189, 500-512.	2.5	4
126	Survivinâ€™ Acute Myeloid Leukaemiaâ€”A Personalised Target for inv(16) Patients. International Journal of Molecular Sciences, 2021, 22, 10482.	4.1	4

#	Article	IF	Citations
127	Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. Oncotarget, 2017, 8, 67891-67903.	1.8	4
128	CYTOGENETIC AND MOLECULAR ANALYSIS OF RELAPSE FOLLOWING BONE MARROW TRANSPLANTATION. British Journal of Haematology, 1990, 75, 631-632.	2.5	3
129	Differential display as an approach to study differentiation and differentiation therapy in AML. Hematological Oncology, 2000, 18, 129-140.	1.7	3
130	Novel observation of three FLT3 codons mutated in tandem in an elderly acute myeloid leukaemia patient. British Journal of Haematology, 2006, 132, 116-117.	2.5	3
131	Screening for miRNA Expression Changes Using Quantitative PCR (Q-PCR). Methods in Molecular Biology, 2012, 863, 293-302.	0.9	3
132	Altered methylation levels in elderly acute myeloid leukaemia patients compared to elderly well individuals. British Journal of Haematology, 2013, 161, 294-296.	2.5	3
133	Differential expression ofSHP-1in chronic myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 1547-1549.	1.3	3
134	New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia. Cancer Immunology, Immunotherapy, 2020, 69, 867-877.	4.2	3
135	An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy.. Blood, 2006, 108, 103-103.	1.4	3
136	Increased circulating normal and BCR-ABL+Ve progenitor numbers in Philadelphia chromosome-positive acute myeloid leukaemia. Leukemia Research, 2002, 26, 997-1005.	0.8	2
137	The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. Leukemia, 2006, 20, 1883-1885.	7.2	2
138	Detecting DNA Methylation Using the Methylated CpG Island Amplification and Microarray Technique. Methods in Molecular Biology, 2012, 863, 329-339.	0.9	2
139	Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia. International Journal of Molecular Sciences, 2021, 22, 10163.	4.1	2
140	Micro-Array and Protein Analyses Reveal a Preferential Autocrine VEGF Survival Loop in CD38+ Sub-Clones When Compared with CD38â^' Sub-Clones Derived from the Same CLL Patient.. Blood, 2005, 106, 180-180.	1.4	2
141	The Aurora Kinase Inhibitor AZD1152 Causes Perturbation of Cell Cycle Distribution in Cell Lines and Primary AML Samples.. Blood, 2005, 106, 2759-2759.	1.4	2
142	Azacytidine as a Maintenance Therapy in Elderly AML Progressively Demethylates CpG Sites within the p16 Gene. Blood, 2008, 112, 4466-4466.	1.4	2
143	Protein migration from transplanted nuclei in Amoeba proteus I. The relation to the cell cycle and RNA migration, as studied by autoradiography. Experimental Cell Research, 1982, 142, 207-213.	2.6	1
144	Specificity of ribozymes against the bcr-abl mRNAs in vitro. Biochemical Society Transactions, 1996, 24, 409S-409S.	3.4	1

#	Article	IF	Citations
145	Methods For the Molecular Analysis of Cancer: An Overview. Molecular Biotechnology, 2003, 23, 167-170.	2.4	1
146	Assessment of the cellular response to the induced expression of defensin sense and antisense cDNA in acute promyelocytic leukemia cell lines. Leukemia and Lymphoma, 2005, 46, 743-752.	1.3	1
147	Molecular genetics. , 2010, , 90-110.		1
148	Persistence of <scp>DNMT</scp>3A does not influence clinical outcome in acute myeloid leukaemia. British Journal of Haematology, 2016, 175, 185-186.	2.5	1
149	NF Kappa B as a Therapeutic Target in AML.. Blood, 2005, 106, 2770-2770.	1.4	1
150	Isolation of Molecular Hybridisation Probes for Early Myeloid Lineage RNAs. Annals of the New York Academy of Sciences, 1987, 511, 308-317.	3.8	0
151	Molecular Analysis of Cancer: An Overview. , 2002, 68, 001-005.		0
152	Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia. EBioMedicine, 2015, 2, 487-488.	6.1	0
153	Compositional analysis gives insight into leukaemia cell lines expression profiles compared to those within patient subâ€groups. British Journal of Haematology, 2018, 181, 847-851.	2.5	0
154	Living Long and Aging Well. , 2018, , 137-152.		0
155	The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.. Blood, 2005, 106, 2981-2981.	1.4	0
156	Inhibition of Cellular Aminopeptidases as Novel Therapy for AML.. Blood, 2006, 108, 2588-2588.	1.4	0
157	PHF23: A Novel Erythropoietin-Induced Gene Associated with AML and MDS.. Blood, 2007, 110, 3178-3178.	1.4	0
158	Comprehensive Genomic Screens Reveal Multiple Modes of Action of the PLZF-RAR-Î± Oncoprotein. Blood, 2008, 112, 686-686.	1.4	0
159	Identifying an Acetylation Signature Following Vorinostat Treatment in AML. Blood, 2012, 120, 1291-1291.	1.4	0
160	Arrested Differentiation in Acute Myeloid Leukemia (AML) with Silenced Ankyrin Repeat and SOCS Box Protein 3 (ASB3) Expression. Blood, 2012, 120, 1232-1232.	1.4	0
161	Epigenetic Silencing of BCL2, ETS1, IL27RA and DICER1 in Low-Risk MDS Patients. Blood, 2012, 120, 1704-1704.	1.4	0
162	Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes. Blood, 2012, 120, 3857-3857.	1.4	0

#	Article	IF	Citations
163	Conditional Deletion of the Hoxa Cluster in MLL-AF9 Is Incompatible with Leukemia Maintenance. Blood, 2015, 126, 3630-3630.	1.4	0
164	Loss of Function Cohesin Complex Gene Mutations Create Neomorphic Cell States Advantageous to Oncogenesis. Blood, 2016, 128, 1564-1564.	1.4	0
165	Relationship between HUWE1 Mutation and Functionality in Multiple Myeloma. Blood, 2018, 132, 4512-4512.	1.4	0
166	The Potential of Using DNA Damage Repair Deficiency As a Biomarker for Cytarabine Response in AML Patients. Blood, 2018, 132, 2812-2812.	1.4	0
167	Identifying Combination Therapies Targeting Apoptosis Pathways in Pediatric Acute Myeloid Leukemia (CAuSAL Study). Blood, 2018, 132, 2731-2731.	1.4	0